|
Lab21 Ltd to Provide AdnaGen's CE-Marked System for the Detection and Analysis of Circulating Tumor Cells (CTCs) in the UK and IrelandOncoVista Innovative Therapies, Inc. Announces the Initiation of Clinical Development of AdnaGen's Breast Cancer Circulating Tumor Cell (CTC) Diagnostic Technology in Women with High-RIsk Locally Advanced Breast CancerAdnaGen AG Completes Successful Fincial Restructuring
CTRC at UTHSCSA and OncoVista Innovative Therapies Announce the Initiation of Collaboration on the Clinical Development of OVI-117
Key U.S. Patent for AdnaGen Technology for the Detection and Analysis of Circulating Tumor Cells is IssuedSysmex Europe GmbH to distribute products for the analysis of circulating tumor cells in different tumor entities developed by AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc.OncoVista Innovative Therapies, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare ConferenceOncoVista Innovative Therapies, Inc. Announces Initiation of Research Coverage by Status Equity ResearchOncoVista Innovative Therapies to Begin Enrolling Patients in a Phase I/II Study of Cordycepin in Patients with Refractory TdT-Positive LeukemiaOncoVista Increases Ownership of AdnaGen AG - Ownership is Increased to 95%OncoVista Innovative Therapies' Information to be Available Through S&P Market Access ProgramOncoVista Innovative Therapies, Inc. Announces Submission of Request for pre-IDE MeetingOncoVista Innovative Therapies, Inc. Announces Appointment of AdnaGen Chief Executive Officer OncoVista Innovative Therapies, Inc. is Trading on the Frankfurt Stock Exchange Effective March 25, 2008 OncoVista Innovative Therapies, Inc, Changes Name from Aviation Upgrade Technologies Effective January 8, 2008 -New Ticker Symbol "OVIT" Effective January 14, 2008 OncoVista Innovative Therapies, Inc. Appoints J. Michael Edwards New Chief Financial Officer OncoVista Increases Its Share in AdnaGen AG
OncoVista Licenses Phase II Clinical-Stage Drug From OSI Pharmaceuticals OncoVista, Inc. Merges with Aviation Upgrade Technologies - OncoVista Now Public Corporation OncoVista to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference Aviation Upgrade Technologies enters into merger agreement with OncoVista, Inc. AdnaGen signs exclusive agreement with Innogenetics to develop and commercialize new multiplex oncology tests OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company Innogenetics to distribute AdnaGen's CE-marked kits for breast and colon cancer in Europe OncoVista acquires controlling interest in AdnaGen AG MSNBC – ILEX co-founder spearheading new anti-cancer drug company By Mike W. Thomas, San Antonio Business Journal |
